bioRxiv · 10.1101/2024.06.21.600073
DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD)
Abstract
Homologous recombination deficiency (HRD) is a predictive biomarker for efficacy of PARP inhibition and platinum chemotherapy but remains challenging to detect from low tumor fraction samples such as liquid biopsies. Here, we describe DirectHRD, a whole-genome sequencing (WGS) scar-based classifier that is 10x more sensitive than state-of-the-art methods. DirectHRD can detect HRD at >=1% tumor fraction using 50x WGS of cell-free DNA.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, R., Roberts, E., Parsons, H. A., Stover, E. H., Choudhury, A. D., Rhoades, J., Blewett, T., Yang, D. D., Liu, J. F., Mayer, E. L., Adalsteinsson, V. A.. 2024-06-27. DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD). https://doi.org/10.1101/2024.06.21.600073
Cite the original work for its findings. Save a collection to share your selection of sources.